|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently it was shown that patients with pituitary corticotrope adenomas respond to GHS with a dramatic rise in ACTH secretion, and it has been suggested that GHS may provide a diagnostic tool to differentiate Cushing's disease from the ectopic ACTH syndrome.
|
9437242 |
1997 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prognostic usefulness of ACTH in the postoperative period of Cushing's disease.
|
31394502 |
2019 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pituitary magnetic resonance imaging (MRI) revealed a 3.5 mm microadenoma and inferior petrosal sinus sampling of adrenocorticotropic hormone (ACTH) after corticotropin releasing hormone (CRH) stimulation confirmed ACTH-dependent CD.
|
31251726 |
2019 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pharmacological targeting of HSF1 may be a promising treatment option for the control of excess ACTH secretion in CD.
|
30995664 |
2019 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with Cushing's disease and ectopic ACTH producing tumors showed elevated levels of androgens and their metabolites when compared with healthy controls.
|
31201926 |
2019 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings provide a plausible cellular basis for the exaggerated ACTH response to ghrelin in Cushing's disease and suggest novel research strategies to develop medical treatments for this disease.
|
16551736 |
2006 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Octreotide, a somatostatin receptor type 2 (SSTR2)-preferring somatostatin analogue, has no effect on ACTH secretion in patients with Cushing's disease.
|
25011056 |
2014 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
OBJECT Functional corticotroph pituitary adenomas (PAs) secrete adrenocorticotropic hormone (ACTH) and are the cause of Cushing's disease, which accounts for 70% of all cases of Cushing's syndrome.
|
25639319 |
2015 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Northern blot analysis revealed that the size of pro-opiomelanocortin mRNA present in the SCCA tissue was indistinguishable from that in the adenomas associated with Cushing's disease.
|
2153197 |
1990 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
No PC2 messenger ribonucleic acid could be detected in the small cell carcinoma of the lung-derived DMS-79 human cell line, which produces unprocessed POMC, or in three pituitary tumors responsible for Cushing's disease or Nelson's syndrome, which produced intact ACTH, but no CLIP.
|
7962350 |
1994 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Next to the traditional tests, a cutoff of preoperative ACTH/cortisol ratio, an ultrasensitive late night salivary cortisol assay and the desmopressin test have been suggested as valid tools for the diagnosis and differential diagnosis of CD.
|
30130808 |
2019 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
NEPVs for cortisol and ACTH predicted nonremission after TSS for CD.
|
28323961 |
2017 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Nelson's syndrome is the appearance and/or progression of ACTH-secreting pituitary macroadenomas in patients who had previously undergone bilateral adrenalectomy for Cushing's disease.
|
8550738 |
1996 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Nelson's syndrome (NS) is characterized by the appearance and/or progression of ACTH-secreting pituitary macroadenomas in patients who had previously undergone bilateral adrenalectomy for the treatment of Cushing's disease.
|
19655257 |
2011 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, clinical manifestations of CD may vary depending on hormonal activity; however, factors involved in the hormonal aggressiveness of adrenocorticotropic hormone (ACTH)-secreting pituitary tumors have not been fully clarified.
|
30474823 |
2019 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Microadenomas that strongly express POMC were common among mutated tumors, which may lead to the mechanisms by which very small adenomas secrete excess ACTH to present overt CD.
|
26578638 |
2016 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Long-term outcomes of tissue-based ACTH-antibody assay-guided transsphenoidal resection of pituitary adenomas in Cushing disease.
|
29027854 |
2018 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Knosp grade 4 adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma is a rare cause of Cushing disease.
|
30431585 |
2018 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Its diagnosis relies on both biochemical tests (high-dose dexamethasone suppression test, ACTH level, corticotropin-releasing hormone test) to confirm ACTH-dependent CD and image studies (CT or MRI of chest, abdomen, and/or pelvis) for source localization.
|
31019854 |
2019 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Investigations suggested Cushing's disease; there was suppression after high-dose dexamethasone (<20 nmol/liter) and a 950% increase in ACTH after stimulation with CRH.
|
11788623 |
2002 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the CD group only, lumbar BMD and serum adrenocorticotropic hormone had a significant positive correlation.
|
28851260 |
2018 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In human patients, somatic mutations in USP8 were identified as the underlying cause of adrenocorticotropic hormone (ACTH) releasing pituitary adenomas causing Cushing's disease (CD).
|
31845722 |
2019 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In each section, we endeavor to correlate basic mechanisms of ACTH function with the pathological consequences of ACTH signaling deficiency and of overproduction of ACTH.
|
26793988 |
2016 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the DDAVP stimulation test, i.e., determination of plasma ACTH levels after 5 microg DDAVP injection, seems useful for discriminating Cushing's disease from normality, and may serve to facilitate the differentiation between Cushing's disease and ectopic ACTH syndrome.
|
9466324 |
1997 |
|
Pituitary-dependent Cushing's disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In a patient with full-blown features of Cushing's syndrome with equivocal ACTH levels, and a pituitary microadenoma on contrast-enhanced MRI sella, can falsely lead to a diagnosis of Cushing's disease.
|
28356253 |
2017 |